Adempas

Chemical Nameriociguat
Dosage FormTablet (oral; 0.5 mg, 1 mg, 1.5 mg, 2 mg, 2.5 mg)
Drug ClassVasodilators
SystemCardiovascular
CompanyBayer
Approval Year2013

Indication

  • For the treatment of persistent/recurrent Chronic Thromboembolic Pulmonary Hypertension (CTEPH) (WHO Group 4) in adults after surgical treatment or inoperable CTEPH to improve exercise capacity and WHO functional class.
  • For the treatment of Pulmonary Arterial Hypertension (PAH) (WHO Group 1) in adults to improve exercise capacity, improve WHO functional class, and to delay clinical worsening.
Last updated on 6/22/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Adempas (riociguat) Prescribing Information.2021Bayer HealthCare Pharmaceuticals Inc.,Whippany, NJ